MuLBSTA score is a useful tool for predicting COVID-19 disease behavior

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Clinical Scoring Systems

Background:

• Predicting COVID-19 progression early is crucial but challenging.
• The MuLBSTA score previously predicted mortality in viral pneumonia but lacked validation for COVID-19.
• Validating existing scoring systems for novel pathogens is essential for clinical management.

Purpose of the Study:

• To validate the MuLBSTA score for predicting disease worsening in COVID-19 patients.
• To assess the utility of the MuLBSTA score in stratifying COVID-19 severity.
• To determine the predictive accuracy of the MuLBSTA score for adverse outcomes.

Main Methods:

• Retrospective analysis of 72 COVID-19 patients treated between April 2020 and March 2021.
• Patients categorized into mild, moderate, and severe groups based on respiratory failure.
• MuLBSTA score applied to assess risk of progression; sensitivity and specificity calculated.

Main Results:

• Among 46 mild cases, 17 progressed; MuLBSTA score had 100% sensitivity and 34.5% specificity at a cut-off of 5.
• Among 55 mild/moderate cases, 6 progressed to severe; MuLBSTA score had 83.3% sensitivity and 71.4% specificity at a cut-off of 11.
• The MuLBSTA score demonstrated varying predictive performance depending on the chosen cut-off and patient cohort.

Conclusions:

• The MuLBSTA score is a potentially valuable tool for predicting COVID-19 disease trajectory.
• This scoring system can aid in identifying patients at high risk of progressing to life-threatening conditions.
• Further validation may refine its use in clinical decision-making for COVID-19 management.